查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1595202

乙酰胺酚静脉静脉注射市场：依适应症、应用、最终用途分类 - 2025-2030 年全球预测

Paracetamol IV Market by Indication (Pain, Pyrexia/Fever), Application (Non-surgical, Surgical), End-use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年乙酰胺酚静脉注射市场价值为94079万美元，预计到2024年将达到100813万美元，复合年增长率为7.64%，预计到2030年将达到157545万美元。

静脉注射乙酰胺酚通常用作镇痛和解热剂，特别是在无法口服给药的临床环境中，静脉注射可快速缓解疼痛和发烧。在手术、急诊和严重监护环境中需要静脉注射乙酰胺酚，在这些环境中即时控制疼痛至关重要，这使其成为医院和专科诊所的重要选择。乙酰胺酚静脉注射不仅用于缓解疼痛，还用于退烧和术后疼痛管理，使其成为手术全期医疗照护的重要组成部分。随着医疗保健领域对有效疼痛管理的需求不断增加，静脉静脉注射乙酰胺酚的最终用途正在扩展到医院、门诊诊所和门诊手术中心。

主要市场统计
基准年[2023] 94079万美元
预测年份 [2024] 1,008.13 百万美元
预测年份 [2030] 15.7545亿美元
复合年增长率（%） 7.64%

乙酰胺酚静脉注射市场的成长受到医疗保健支出增加、外科手术数量增加以及对疼痛管理通讯协定认识不断增强的强烈影响。此外，新兴国家医疗保健基础设施的扩张正在为市场参与企业和现有参与者创造有利可图的机会。为了抓住这些机会，公司可能会专注于透过联合研究和销售合作伙伴关係来提高产品可用性，特别是在人口稀少的市场。儘管存在这些成长要素，但市场仍面临一些限制，例如与药物过量相关的副作用、严格的监管要求以及阻碍市场扩张的替代镇痛药的竞争。

该领域的创新可能包括配方改进，以提高药物疗效、减少副作用并延长静脉注射配方的保质期。此外，药物输送系统的进步，例如智慧输注技术，可能会提供竞争优势。对患者量身定制的给药方案的研究以及人工智慧驱动工具的整合以监测患者的反应可以进一步推进其应用和广泛使用。该市场的特点是适度分散，主要参与者不断透过策略联盟和研发来竞争扩张。富有洞察力的分析和持续创新对于克服挑战并释放乙酰胺酚静脉静脉注射市场的开拓潜力至关重要。

市场动态：快速发展的乙酰胺酚静脉静脉注射市场的关键市场洞察

供需的动态交互作用正在改变静脉注射乙酰胺酚市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 指定疾病和病症的盛行率不断增加
    • 增加静脉注射乙酰胺酚的使用以减少手术后的发烧
    • 加强对乙酰胺酚的使用以减少阿片类药物对疼痛管理的依赖
  • 市场限制因素
    • 多种学名药的可用性
  • 市场机会
    • 政府措施和活性化的研发活动
    • 静脉注射乙酰胺酚与非类固醇消炎剂(NSAID) 或麻醉药合併使用
  • 市场挑战
    • 缺乏经验丰富的医疗保健专业人员

波特五力：驾驭乙酰胺酚静脉静脉注射市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解乙酰胺酚静脉注射市场的外部影响

外部宏观环境因素在塑造乙酰胺酚静脉静脉注射市场的表现动态中起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解乙酰胺酚静脉静脉注射市场的竞争状况

对乙酰胺酚静脉注射市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵乙酰胺酚静脉静脉注射市场供应商绩效评估

FPNV 定位矩阵是评估乙酰胺酚静脉静脉注射市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製乙酰胺酚静脉注射市场的成功之路

对乙酰胺酚静脉注射市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 征兆的疾病和症状的盛行率增加
      • 手术后增加静脉注射乙酰胺酚的使用以缓解发烧
      • 加强对乙酰胺酚的使用以减少疼痛管理中对鸦片类药物的依赖
    • 抑制因素
      • 多种学名药的可用性
    • 机会
      • 增加政府措施和研发活动
      • 将静脉注射乙酰胺酚与非类固醇消炎剂(NSAID) 和麻醉药合併使用
    • 任务
      • 缺乏经验丰富的医疗保健专业人员
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章乙酰胺酚静脉注射市场依适应症分类

  • 疼痛
  • 发烧

第七章乙酰胺酚静脉注射市场：依应用分类

  • 非手术的
  • 外科手术

第八章乙酰胺酚静脉静脉注射市场：依最终用途分类

  • 诊所
  • 医院

第九章 北美、南美乙酰胺酚静脉注射市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章 亚太地区乙酰胺酚静脉注射市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东及非洲乙酰胺酚静脉注射市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Aurobindo Pharma Ltd.
  • Biological E. Limited
  • Cfl Pharmaceuticals Limited
  • Changshu Huagang Pharmaceuticals Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Geno Pharmaceuticals Private Limited
  • Hebei Jiheng Pharmaceutical Co.,Ltd.
  • Huzhou Konch Pharmaceutical Co., Ltd.
  • Lupin Pharmaceuticals, Inc.
  • Mallinckrodt PLC
  • Novartis AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zhejiang Kangle Pharmaceutical Co., Ltd.
Product Code: MRR-F927BA4629AD

The Paracetamol IV Market was valued at USD 940.79 million in 2023, expected to reach USD 1,008.13 million in 2024, and is projected to grow at a CAGR of 7.64%, to USD 1,575.45 million by 2030.

Paracetamol IV, often used as an analgesic and antipyretic, is administered intravenously for rapid relief from pain and fever, particularly in clinical settings where oral administration is not feasible. The necessity of Paracetamol IV arises in surgical, emergency, and critical care scenarios where immediate pain management is vital, making it a crucial option in hospitals and specialty clinics. Its application is not only limited to pain relief but also spans the management of fever and post-operative pain, making it indispensable in perioperative care. As demand for effective pain management in healthcare rises, the end-use scope for Paracetamol IV is broadening, spanning hospitals, outpatient clinics, and ambulatory surgery centers.

KEY MARKET STATISTICS
Base Year [2023] USD 940.79 million
Estimated Year [2024] USD 1,008.13 million
Forecast Year [2030] USD 1,575.45 million
CAGR (%) 7.64%

Market growth for Paracetamol IV is strongly influenced by increasing healthcare expenditure, rising surgical procedures, and growing awareness regarding pain management protocols. Furthermore, the expansion of healthcare infrastructure in emerging economies presents lucrative opportunities for market entrants and existing players. To capture these opportunities, companies could focus on increasing product availability through collaborations or distribution partnerships, particularly in underpenetrated markets. Despite these growth drivers, the market faces limitations such as adverse effects associated with overdosage, stringent regulatory requirements, and competition from alternative analgesics, which can hinder its expansion.

Innovation in this sector could involve enhancing drug formulation to increase efficacy, reduce side effects, or extend the shelf life of the IV form. Additionally, advancements in drug delivery systems, such as smart infusion technology, can present a competitive edge. Research into patient-tailored dosing regimens and the integration of AI-driven tools for monitoring patient response could further refine its application and uptake. The market is characterized by moderate fragmentation with key players constantly vying for expansion through strategic collaborations and R&D. Insightful analysis and continuous innovation are crucial for navigating the challenges and tapping into the untapped potential of the Paracetamol IV market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Paracetamol IV Market

The Paracetamol IV Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of indicative diseases and conditions
    • Increasing use of paracetamol IV in relieving fever in post-surgical procedures
    • Enhanced usage of acetaminophen to reduce the dependence on opioids for pain management
  • Market Restraints
    • Availability of multiple generic products
  • Market Opportunities
    • Government initiatives and rising research and development activities
    • Use of paracetamol IV in combination with non-steroidal anti-inflammatory drugs (NSAID) and narcotics
  • Market Challenges
    • Lack of experienced healthcare professionals

Porter's Five Forces: A Strategic Tool for Navigating the Paracetamol IV Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Paracetamol IV Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Paracetamol IV Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Paracetamol IV Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Paracetamol IV Market

A detailed market share analysis in the Paracetamol IV Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Paracetamol IV Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Paracetamol IV Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Paracetamol IV Market

A strategic analysis of the Paracetamol IV Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Paracetamol IV Market, highlighting leading vendors and their innovative profiles. These include Aurobindo Pharma Ltd., Biological E. Limited, Cfl Pharmaceuticals Limited, Changshu Huagang Pharmaceuticals Co., Ltd., Dr. Reddy's Laboratories Ltd., Geno Pharmaceuticals Private Limited, Hebei Jiheng Pharmaceutical Co.,Ltd., Huzhou Konch Pharmaceutical Co., Ltd., Lupin Pharmaceuticals, Inc., Mallinckrodt PLC, Novartis AG, Sanofi S.A., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., and Zhejiang Kangle Pharmaceutical Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Paracetamol IV Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Pain and Pyrexia/Fever.
  • Based on Application, market is studied across Non-surgical and Surgical.
  • Based on End-use, market is studied across Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of indicative diseases and conditions
      • 5.1.1.2. Increasing use of paracetamol IV in relieving fever in post-surgical procedures
      • 5.1.1.3. Enhanced usage of acetaminophen to reduce the dependence on opioids for pain management
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of multiple generic products
    • 5.1.3. Opportunities
      • 5.1.3.1. Government initiatives and rising research and development activities
      • 5.1.3.2. Use of paracetamol IV in combination with non-steroidal anti-inflammatory drugs (NSAID) and narcotics
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of experienced healthcare professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Paracetamol IV Market, by Indication

  • 6.1. Introduction
  • 6.2. Pain
  • 6.3. Pyrexia/Fever

7. Paracetamol IV Market, by Application

  • 7.1. Introduction
  • 7.2. Non-surgical
  • 7.3. Surgical

8. Paracetamol IV Market, by End-use

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Hospitals

9. Americas Paracetamol IV Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Paracetamol IV Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Paracetamol IV Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aurobindo Pharma Ltd.
  • 2. Biological E. Limited
  • 3. Cfl Pharmaceuticals Limited
  • 4. Changshu Huagang Pharmaceuticals Co., Ltd.
  • 5. Dr. Reddy's Laboratories Ltd.
  • 6. Geno Pharmaceuticals Private Limited
  • 7. Hebei Jiheng Pharmaceutical Co.,Ltd.
  • 8. Huzhou Konch Pharmaceutical Co., Ltd.
  • 9. Lupin Pharmaceuticals, Inc.
  • 10. Mallinckrodt PLC
  • 11. Novartis AG
  • 12. Sanofi S.A.
  • 13. Sun Pharmaceutical Industries Limited
  • 14. Teva Pharmaceutical Industries Ltd.
  • 15. Zhejiang Kangle Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. PARACETAMOL IV MARKET RESEARCH PROCESS
  • FIGURE 2. PARACETAMOL IV MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PARACETAMOL IV MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PARACETAMOL IV MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PARACETAMOL IV MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PARACETAMOL IV MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PARACETAMOL IV MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PARACETAMOL IV MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PARACETAMOL IV MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS PARACETAMOL IV MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS PARACETAMOL IV MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES PARACETAMOL IV MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES PARACETAMOL IV MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PARACETAMOL IV MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC PARACETAMOL IV MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PARACETAMOL IV MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PARACETAMOL IV MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. PARACETAMOL IV MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. PARACETAMOL IV MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PARACETAMOL IV MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PARACETAMOL IV MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PARACETAMOL IV MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PARACETAMOL IV MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PARACETAMOL IV MARKET DYNAMICS
  • TABLE 7. GLOBAL PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PARACETAMOL IV MARKET SIZE, BY PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PARACETAMOL IV MARKET SIZE, BY PYREXIA/FEVER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PARACETAMOL IV MARKET SIZE, BY NON-SURGICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PARACETAMOL IV MARKET SIZE, BY SURGICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PARACETAMOL IV MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PARACETAMOL IV MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS PARACETAMOL IV MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES PARACETAMOL IV MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC PARACETAMOL IV MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA PARACETAMOL IV MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 143. PARACETAMOL IV MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 144. PARACETAMOL IV MARKET, FPNV POSITIONING MATRIX, 2023